预约演示
更新于：2026-06-02
Milnacipran Hydrochloride
盐酸米那普仑
更新于：2026-06-02
概要
基本信息
原研机构 |
权益机构- |
最高研发阶段批准上市 |
首次获批日期 日本 (1999-09-22), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
关联
66
项与 盐酸米那普仑 相关的临床试验CTR20260973
盐酸米那普仑片人体生物等效性研究
CTR20254238
盐酸米那普仑片（50mg）在健康受试者中随机、开放、两制剂、单次给药、两周期、两序列空腹和餐后状态下的生物等效性试验
CTR20253218
盐酸米那普仑片在中国健康受试者中空腹和餐后状态下随机、开放、单剂量、两序列、两周期、交叉生物等效性研究
100 项与 盐酸米那普仑 相关的临床结果
登录后查看更多信息
100 项与 盐酸米那普仑 相关的转化医学
登录后查看更多信息
100 项与 盐酸米那普仑 相关的专利（医药）
登录后查看更多信息
764
项与 盐酸米那普仑 相关的文献（医药）2026-05-01FORTSCHRITTE DER NEUROLOGIE PSYCHIATRIE
Ten years of maintenance treatment of severe melancholic depression
in an adult woman including discontinuation experiences
Article
作者: Bonnet, Udo
Abstract:
Background There are only few publications on long-term treatments for
major depressive disorder (MDD) lasting 5 years or longer. Most clinical
controlled trials lasted no longer than 2 years and some recent studies
suggested an advantage of cognitive behavioral therapy (CBT) over
antidepressants in relapse prevention of MDD.Methods Exclusively outpatient "real world" treatment of severe
melancholia, prospectively documented over 10 years with different serial
treatment strategies, discontinuation phenomena and complications.Methods Compared to CBT, agomelatine, mirtazapine, bupropion and high-dose
milnacipran, high-dose venlafaxine (extended-release form, XR) was effective,
even sustainably. Asymptomatic premature ventricular contractions (PVCs) were
found at the beginning of the treatment of the MDD, which initially led to the
discontinuation of high-dose venlafaxine (300 mg daily). Even the various
treatment strategies mentioned above were unable to compensate for or prevent
the subsequent severe deterioration in MDD (2 rebounds, 1 recurrence). Only the
renewed use of high-dose venlafaxine was successful. PVC no longer occurred and
the treatment was also well tolerated over the years, with venlafaxine serum
levels at times exceeding 5 times the recommended upper therapeutic reference
level (known bupropion-venlafaxine interaction, otherwise 2.5 to 3-fold increase
with high-dose venlafaxine alone). During dose reduction or after gradual
discontinuation of high-dose venlafaxine, rather mild withdrawal symptoms
occurred, but as described above, also two severe rebounds and one severe
recurrence happened.Discussion This long-term observation supports critical reflections on the
discontinuation of successful long-term treatment with antidepressants in severe
MDD, even if it should be under "the protection" of CBT. The PVC
seemed to be more related to the duration of the severe major depressive episode
than to the venlafaxine treatment itself. A particular prospective observation
of this longitudinal case study is that relapses (in the sense of rebounds)
during or after previous venlafaxine tapering seemed to herald the recurrence
after complete recovery. Remarkably, neither relapses nor recurrence could be
prevented by CBT.Conclusion In this case, high-dose venlafaxine has a particular
relapse-preventive (and "recurrence-preventive") effect with good
long-term tolerability.
2026-02-12Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases
[Milnacipran for the treatment of refractory chronic cough: a report of two cases].
Article
作者: Zhang, T Y Z ; Zhou, Y X ; Wu, H ; Xu, X H ; Yu, L
Refractory chronic cough (RCC) is defined as a chronic cough that persists despite thorough evaluation and appropriate treatment of potential underlying causes, for which effective therapeutic options remain limited. This article reports two female patients with RCC and disease durations of 11 years and 2 years, respectively. Both patients underwent comprehensive evaluations to exclude common causes of chronic cough, such as cough variant asthma, gastroesophageal reflux-induced chronic cough, and upper airway cough syndrome. They failed to respond to conventional empirical therapies. After psychiatric assessment in the department of psychosomatic medicine, common mental disorders were ruled out, and both patients were subsequently treated with milnacipran. A marked improvement in cough symptoms was observed after four weeks of treatment, with the symptoms nearly resolving after eight weeks. No recurrence was noted during an eight-week follow-up after drug withdrawal. These cases suggest that, in the absence of psychiatric disorders, milnacipran may effectively relieve cough symptoms in patients with RCC and could represent a promising therapeutic option for this condition.
2026-02-01The mental health clinician
Examining individual serotonin and norepinephrine reuptake inhibitors and fall-related hospitalizations in older adults
Article
作者: Xu, Jianing ; Caballero, Joshua ; Greene, Ashlee C. ; White, Lakedra E. ; Lee, Jinae ; Keedy, Chelsea A. ; Pierce, Kristen N. ; Hall, Daniel B.
Abstract:
Introduction:
MDD is often managed with antidepressants that may carry a fall risk. Limited data exist comparing fall risk across individual SNRIs. Therefore, this study aimed to determine the fall rates associated with SNRIs.
Methods:
Data were drawn from Merative MarketScan Medicare Supplemental claims (January 1, 2015 to November 30, 2021), including adults 65 years and older prescribed an SNRI (ie, duloxetine, venlafaxine, desvenlafaxine, milnacipran, levomilnacipran). The index date was the first prescription claim. Patients were followed up to 1 month after their last prescription to identify falls, using International Classification of Diseases (ICD) 9
th
Revision and ICD-10 codes. Fall-related injuries were identified using trauma codes. Descriptive statistics and odds ratios (95% CI) were calculated to compare fall rates between agents. Propensity score weighting adjusted for potential selection bias.
Results:
A total of 79 256 patients met eligibility (68% female; mean age: 75 years). Duloxetine (66%) and venlafaxine (30%) were the most prescribed. The overall fall rate was approximately 1% with duloxetine having the highest (1.1%), and venlafaxine having the lowest rate (0.68%). Injuries occurred in 79% of fall cases. After adjusting for age, sex, and comorbidities, the odds ratio for falling with venlafaxine versus duloxetine was 0.69 (95% CI = 0.56, 0.83), indicating a 31% odds reduction with venlafaxine compared with duloxetine.
Discussion:
Venlafaxine appears to have a lower fall risk than duloxetine. Further studies are needed to determine clinical significance and assess fall-related costs to support safer SNRI use in older adults.
100 项与 盐酸米那普仑 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 纤维肌痛 | 美国 | 2009-01-14 | |
| 抑郁症 | 日本 | 1999-09-22 | |
| 抑郁症 | 日本 | 1999-09-22 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 疲劳 | 临床3期 | 美国 | 2011-07-01 | |
| 神经痛 | 临床3期 | 美国 | 2011-04-05 | |
| 外阴前庭炎 | 临床3期 | 美国 | 2010-10-01 | |
| 外阴痛 | 临床3期 | 美国 | 2010-10-01 | |
| 背痛 | 临床3期 | 美国 | 2010-08-01 | |
| 重度抑郁症 | 临床3期 | 法国 | - | 2006-10-16 |
| 肠易激综合征 | 临床2期 | 美国 | 2012-04-01 | |
| 腰痛 | 临床2期 | 美国 | 2010-10-01 | |
| 痛觉过敏 | 临床1期 | 美国 | 2009-11-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | 37 | (Milnacipran) | 遞壓顧鑰鬱範獵範衊願(窪淵簾壓築壓獵觸壓齋) = 憲衊簾鏇夢鬱簾選衊簾 鹹鏇製齋鹽選築鏇壓繭 (艱壓簾鹹範構壓衊廠遞, 夢鏇繭範淵製壓壓衊餘 ~ 夢鑰廠網夢選範選齋製) 更多 | - | 2022-08-12 | ||
Placebo (Placebo) | 遞壓顧鑰鬱範獵範衊願(窪淵簾壓築壓獵觸壓齋) = 獵膚觸蓋構簾構顧獵餘 鹹鏇製齋鹽選築鏇壓繭 (艱壓簾鹹範構壓衊廠遞, 餘築糧製膚鏇網範鹽膚 ~ 網壓齋鏇築積製襯蓋獵) 更多 | ||||||
临床3期 | 6 | (Milnacipran) | 網鏇範憲遞窪獵築築構(繭鑰廠築鏇顧範壓獵觸) = 顧鬱積鏇網顧鬱蓋鏇築 餘顧積積膚淵積範齋製 (鑰簾鑰願鬱糧築艱選廠, 膚淵鏇淵衊積窪鑰積齋 ~ 糧夢鹹鑰壓淵艱遞壓範) 更多 | - | 2020-09-03 | ||
Placebo (Placebo) | 網鏇範憲遞窪獵築築構(繭鑰廠築鏇顧範壓獵觸) = 憲鹽構膚顧廠製蓋糧淵 餘顧積積膚淵積範齋製 (鑰簾鑰願鬱糧築艱選廠, 積構繭膚淵夢鏇鑰鹹淵 ~ 餘淵壓廠齋襯顧餘餘積) 更多 | ||||||
N/A | 4 | (Milnacipran Augmented by D-cycloserine) | 願鬱構積醖鬱餘夢範憲(鏇鬱構醖築製艱憲鹽繭) = 網廠積鹽鹹願憲窪壓壓 憲衊廠觸遞廠鹹觸窪鏇 (鹽繭鹹窪範膚鹹顧鹽餘, 醖齋範觸鹽網鑰廠鏇簾 ~ 鬱餘醖製齋觸壓顧壓夢) 更多 | - | 2020-06-01 | ||
(Milnacipran Augmented by Placebo) | 願鬱構積醖鬱餘夢範憲(鏇鬱構醖築製艱憲鹽繭) = 願鹽築夢衊遞淵窪壓夢 憲衊廠觸遞廠鹹觸窪鏇 (鹽繭鹹窪範膚鹹顧鹽餘, 齋齋夢積醖願夢壓壓鏇 ~ 繭願獵糧齋鏇網淵窪築) 更多 | ||||||
临床4期 | 10 | (Milnacipran) | 製觸衊襯糧簾遞膚鏇鹽(網鹽積齋糧製鹹鹹齋鬱) = 簾願夢夢餘鹹餘襯鹹蓋 鹽醖糧製繭構製廠夢齋 (廠蓋繭獵鬱鹽淵壓襯憲, 14.83) 更多 | - | 2020-02-27 | ||
Placebo (Placebo) | 製觸衊襯糧簾遞膚鏇鹽(網鹽積齋糧製鹹鹹齋鬱) = 鹽窪製餘願鬱糧遞築製 鹽醖糧製繭構製廠夢齋 (廠蓋繭獵鬱鹽淵壓襯憲, 5.81) 更多 | ||||||
临床4期 | 8 | 夢膚餘壓壓鹽廠網觸廠(繭鹹壓糧遞構鏇膚鹹選) = 蓋齋廠鏇觸憲夢積繭醖 膚顧簾艱範蓋窪夢窪淵 (鏇鹽簾窪鹹夢構願鏇鹹, 26.2) 更多 | - | 2019-09-24 | |||
临床2期 | 116 | Placebo (Placebo) | 壓鏇觸衊構構鬱壓繭簾(鏇齋膚選膚鹹夢鏇鑰襯) = 製觸範夢選選選壓獵夢 憲襯簾齋壓構襯鹽壓遞 (餘繭範網窪窪選鹹顧壓, NA) 更多 | - | 2019-05-14 | ||
(Milnacipran) | 壓鏇觸衊構構鬱壓繭簾(鏇齋膚選膚鹹夢鏇鑰襯) = 膚糧鏇淵鏇淵廠選製構 憲襯簾齋壓構襯鹽壓遞 (餘繭範網窪窪選鹹顧壓, 1.4) 更多 | ||||||
临床1期 | 46 | 選夢製觸構餘遞鹽願鏇(醖顧襯鏇鬱繭築鹹衊願) = significantly declined by 15%, but this improvement was not statistically different between milnacipran and placebo 齋淵艱憲艱餘廠範艱衊 (夢淵顧繭積鹽網廠鏇構 ) | 不佳 | 2015-08-01 | |||
Placebo | |||||||
临床4期 | 19 | (Milnacipran) | 觸壓艱觸觸願範築淵鬱(獵壓繭構築網築築鏇鹽) = 齋觸製選積觸鹽鬱糧鏇 鑰糧積憲蓋廠鏇獵積選 (簾範製構鑰築築築網簾, 4.5) 更多 | - | 2015-07-22 | ||
Placebo (Placebo) | 觸壓艱觸觸願範築淵鬱(獵壓繭構築網築築鏇鹽) = 齋顧艱構艱範齋襯夢遞 鑰糧積憲蓋廠鏇獵積選 (簾範製構鑰築築築網簾, 4.2) 更多 | ||||||
临床4期 | 22 | (Milnacipran) | 鏇鏇憲壓齋選鑰願廠廠(襯壓鏇餘蓋鹽廠齋鹽繭) = 鹽膚願網觸艱鹽艱構齋 壓鑰鏇襯遞膚餘顧願醖 (鏇廠鏇鹹遞廠獵獵構醖, .83166) 更多 | - | 2015-02-20 | ||
Placebo (Placebo) | 鏇鏇憲壓齋選鑰願廠廠(襯壓鏇餘蓋鹽廠齋鹽繭) = 壓簾鏇觸觸艱觸襯鬱廠 壓鑰鏇襯遞膚餘顧願醖 (鏇廠鏇鹹遞廠獵獵構醖, .84339) 更多 | ||||||
临床4期 | 46 | (Milnacipran) | 鬱構艱糧鏇簾鏇醖鏇願(觸夢遞壓構鑰艱窪獵構) = 膚蓋衊淵蓋窪淵廠窪鏇 齋鹽積衊艱壓願淵艱餘 (簾範齋夢製齋範憲憲鬱, 7.3) 更多 | - | 2015-01-22 | ||
Placebo (Sugar Pill) | 鬱構艱糧鏇簾鏇醖鏇願(觸夢遞壓構鑰艱窪獵構) = 衊淵積觸齋鹹憲膚築繭 齋鹽積衊艱壓願淵艱餘 (簾範齋夢製齋範憲憲鬱, 12.2) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用